



## **Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society's 2021 Annual Meeting**

March 2, 2021

SAN FRANCISCO--(BUSINESS WIRE)--Mar. 2, 2021-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that data from its Phase 1 and 2 program of tildacerfont for the treatment of classic congenital adrenal hyperplasia will be shared at the Endocrine Society's 2021 Annual Meeting (ENDO 2021) taking place virtually from Saturday, March 20 to Tuesday, March 23.

Full ePoster presentation details are listed below, and the full preliminary program is available online at the ENDO 2021 [website](#). The presentations will be on display in ENDO 2021's virtual poster hall beginning on Saturday, March 20 at 8:00am PST / 11:00am EST.

### **Tildacerfont for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia: Results From a 12-week Phase 2 Clinical Trial in Adults with Classic CAH**

**Presenter:** Richard J. Auchus, MD, PhD

**Co-Authors:** Richard J. Auchus, MD, PhD, Deborah P. Merke, MD, MS, Ivy-Joan Madu, MD, Samer Nakhle, MD, Kyriakie Sarafoglou, MD, Michael Huang, MD, David Moriarty, PhD, Chris N. Barnes, PhD, and Ron S. Newfield, MD

**Poster Session:** P25, Endocrine Disrupting Compounds: Mechanisms of Action and Clinical Implications

**Abstract Number:** 4308

### **Assessment of Steroid Hormones in Both Saliva and Blood During a Phase 2 Clinical Trial for the Use of Tildacerfont in Adults with Classic Congenital Adrenal Hyperplasia**

**Presenter:** Chris N. Barnes, PhD

**Co-Authors:** Brian Keevil, MSc FRCPATH, Kyriakie Sarafoglou, MD, David Moriarty, PhD, Michael Huang, MD, Chris N. Barnes, PhD, and Wiebke Arlt, MD DSc FRCP FMedSci

**Poster Session:** P54, Hormone Actions in Tumor Biology: From New Mechanisms to Therapy

**Abstract Number:** 4305

### **Dose Escalating and Bioavailability Phase 1 Studies Assessing Safety and Tolerability and Pharmacokinetics of Tildacerfont, A Small-Molecule Oral CRF1 Receptor Antagonist**

**Presenter:** Chris N. Barnes, PhD

**Co-Authors:** Chris N. Barnes, PhD, Elliot Offman, PhD, Nora Darago, BS, and David Moriarty, PhD

**Poster Session:** P04, Adrenal - Basic and Translational Aspects

**Abstract Number:** 4140

### **About Spruce Biosciences**

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210302005405/en/): <https://www.businesswire.com/news/home/20210302005405/en/>

### **Media**

Will Zasadny  
Canale Communications  
(619) 961-8848  
[will@canalecomm.com](mailto:will@canalecomm.com)  
[media@sprucebiosciences.com](mailto:media@sprucebiosciences.com)

### **Investors**

Thomas Hoffmann  
Solebury Trout  
(646) 378-2931  
[thoffmann@soleburytrout.com](mailto:thoffmann@soleburytrout.com)  
[investors@sprucebiosciences.com](mailto:investors@sprucebiosciences.com)

Source: Spruce Biosciences, Inc.